Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.

Conclusions: Based on a willingness-to-pay threshold of EUR 30,000 per QALY gained, once-weekly semaglutide 0.5 mg and 1 mg were projected to be cost-effective versus empagliflozin 10 mg and 25 mg for treatment of patients with T2D with inadequate glycemic control on oral anti-hyperglycemic medications in the Spanish setting, irrespective of patients' BMI at baseline. PMID: 31613199 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31613199?dopt=Abstract

Source: Journal of Medical Economics - October 17, 2019 Category: Health Management Tags: J Med Econ Source Type: research